Skip to main content

Lycium barbarum polysaccharide alleviates dextran sodium sulfate-induced inflammatory bowel disease by regulating M1/M2 macrophage polarization via the STAT1 and STAT6 pathways.

Journal articles  - Journal Article
Wang, J; Gao, H; Xie, Y; Wang, P; Li, Y; Zhao, J; Wang, C; Ma, X; Wang, Y; Mao, Q; Xia, H
Published in: Frontiers in pharmacology
January 2023

Disruption of colonic homeostasis caused by aberrant M1/M2 macrophage polarization contributes to the development of inflammatory bowel disease (IBD). Lycium barbarum polysaccharide (LBP) is the primary active constituent of traditional Chinese herbal Lycium barbarum L., which has been widely demonstrated to have important functions in regulating immune activity and anti-inflammatory. Thus, LBP may protect against IBD. To test this hypothesis, the DSS-induced colitis model was established in mice, then the mice were treated with LBP. The results indicated that LBP attenuated the weight loss, colon shortening, disease activity index (DAI), and histopathological scores of colon tissues in colitis mice, suggesting that LBP could protect against IBD. Besides, LBP decreased the number of M1 macrophages and the protein level of Nitric oxide synthase 2(NOS2) as a marker of M1 macrophages and enhanced the number of M2 macrophages and the protein level of Arginase 1(Arg-1) as a marker of M2 macrophages in colon tissues from mice with colitis, suggesting that LBP may protect against IBD by regulating macrophage polarization. Next, the mechanistic studies in RAW264.7 cells showed that LBP inhibited M1-like phenotype by inhibiting the phosphorylation of STAT1, and promoted M2-like phenotype by promoting the phosphorylation of STAT6. Finally, immunofluorescence double-staining results of colon tissues showed that LBP regulated STAT1 and STAT6 pathways in vivo. The results in the study demonstrated that LBP could protect against IBD by regulating macrophage polarization through the STAT1 and STAT6 pathways.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Frontiers in pharmacology

DOI

EISSN

1663-9812

ISSN

1663-9812

Publication Date

January 2023

Volume

14

Start / End Page

1044576

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, J., Gao, H., Xie, Y., Wang, P., Li, Y., Zhao, J., … Xia, H. (2023). Lycium barbarum polysaccharide alleviates dextran sodium sulfate-induced inflammatory bowel disease by regulating M1/M2 macrophage polarization via the STAT1 and STAT6 pathways. Frontiers in Pharmacology, 14, 1044576. https://doi.org/10.3389/fphar.2023.1044576
Wang, Juan, Huiying Gao, Yuan Xie, Peng Wang, Yu Li, Junli Zhao, Chunlin Wang, et al. “Lycium barbarum polysaccharide alleviates dextran sodium sulfate-induced inflammatory bowel disease by regulating M1/M2 macrophage polarization via the STAT1 and STAT6 pathways.Frontiers in Pharmacology 14 (January 2023): 1044576. https://doi.org/10.3389/fphar.2023.1044576.
Wang, Juan, et al. “Lycium barbarum polysaccharide alleviates dextran sodium sulfate-induced inflammatory bowel disease by regulating M1/M2 macrophage polarization via the STAT1 and STAT6 pathways.Frontiers in Pharmacology, vol. 14, Jan. 2023, p. 1044576. Epmc, doi:10.3389/fphar.2023.1044576.
Wang J, Gao H, Xie Y, Wang P, Li Y, Zhao J, Wang C, Ma X, Wang Y, Mao Q, Xia H. Lycium barbarum polysaccharide alleviates dextran sodium sulfate-induced inflammatory bowel disease by regulating M1/M2 macrophage polarization via the STAT1 and STAT6 pathways. Frontiers in pharmacology. 2023 Jan;14:1044576.

Published In

Frontiers in pharmacology

DOI

EISSN

1663-9812

ISSN

1663-9812

Publication Date

January 2023

Volume

14

Start / End Page

1044576

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences